NCT03399552View on ClinicalTrials.gov

Stereotactic Body Radiation Therapy and Avelumab Immunotherapy for Treatment of Malignant Mesothelioma

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

December 20, 2017

Primary Completion Date

January 20, 2023

Study Completion Date

January 20, 2023

Conditions
Malignant Mesothelioma (MPM)
Interventions
DRUG

Avelumab

10mg/kg delivered by IV infusion

RADIATION

Stereotactic Body Radiation Therapy

short course of SBRT after the first two doses of avelumab

Trial Locations (7)

10065

Memorial Sloan Kettering Cancer Center, New York

10604

Memorial Sloan Kettering Westchester, Harrison

11553

Memorial Sloan Kettering Nassau, Uniondale

11570

Memorial Sloan Kettering Rockville Centre, Rockville Centre

11725

Memorial Sloan Kettering Commack, Commack

07920

Memorial Sloan Kettering at Basking Ridge, Basking Ridge

07748

Memorial Sloan Kettering Monmouth, Middletown

Sponsors

Collaborators (1)

Pfizer
All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT03399552 - Stereotactic Body Radiation Therapy and Avelumab Immunotherapy for Treatment of Malignant Mesothelioma | Biotech Hunter | Biotech Hunter